Thomas Chalopin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thomas Chalopin has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Jill Corre
Cancer Research Center of Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Toulouse, France
8 shared publications Margaret Macro
CHU de Caen, Hématologie, Caen, France
8 shared publications- Xavier Leleu
CHU Poitiers, Hôpital la Milétrie, Poitiers, France
8 shared publications Arthur Bobin
CHU de Poitiers
7 shared publicationsLionel Karlin
Hôpital Lyon Sud, Hématologie, Lyon, France
7 shared publicationsMurielle Roussel
CHU de Limoges, Hématologie, Limoges, France
7 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 110
Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial
- 3 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 110
Open AccessResponse profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial
- Open Access
- 14 April 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (7) , e829-e840.e3
The Value of Progression-Free Survival in the Perspective of Patients with Multiple Myeloma and Treating Physicians: Research Findings from the US, EU4, UK, Brazil, and Japan
- 14 April 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (7) , e829-e840.e3
Open AccessThe Value of Progression-Free Survival in the Perspective of Patients with Multiple Myeloma and Treating Physicians: Research Findings from the US, EU4, UK, Brazil, and Japan
- Open Access
- 20 March 2026
- Published by Springer Nature in Research Square
Subcutaneous Isatuximab by On-Body-Injector plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: ISASOCUT study
Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate treatment administration. ISASOCUT is a prospective, multicenter, phase 2 study evaluating the efficacy and tolerability of Isa SC-VRd administered via OBI. SC isatuximab (1400 mg) was given weekly during cycle 1, then on days 1 and 15 through cycle 12 in combination with VRd, followed by monthly isatuximab–lenalidomide until progression. The primary endpoint was the rate of ≥very good partial response (VGPR) at 8 months. Seventy-four patients were treated, with a median age of 73 years. At 8 months, the ≥VGPR rate was 88% (95% CI, 78–94). Minimal residual disease negativity was achieved in 36% at 10⁻⁵ and 28% at 10⁻⁶. At a median follow-up of 21.2 months, 14-month progression-free and event-free survival rates were 93.1% and 91.7%, respectively. The median relative dose intensity of isatuximab was 91.8%, with 99.3% of injections successfully completed. Infusion-related reactions occurred in 5% of patients, mostly low grade. ISASOCUT met its primary endpoint and supports SC isatuximab via OBI as a feasible alternative to intravenous administration.
- 20 March 2026
- Published by Springer Nature in Research Square
Open AccessSubcutaneous Isatuximab by On-Body-Injector plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: ISASOCUT study
Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate treatment administration. ISASOCUT is a prospective, multicenter, phase 2 study evaluating the efficacy and tolerability of Isa SC-VRd administered via OBI. SC isatuximab (1400 mg) was given weekly during cycle 1, then on days 1 and 15 through cycle 12 in combination with VRd, followed by monthly isatuximab–lenalidomide until progression. The primary endpoint was the rate of ≥very good partial response (VGPR) at 8 months. Seventy-four patients were treated, with a median age of 73 years. At 8 months, the ≥VGPR rate was 88% (95% CI, 78–94). Minimal residual disease negativity was achieved in 36% at 10⁻⁵ and 28% at 10⁻⁶. At a median follow-up of 21.2 months, 14-month progression-free and event-free survival rates were 93.1% and 91.7%, respectively. The median relative dose intensity of isatuximab was 91.8%, with 99.3% of injections successfully completed. Infusion-related reactions occurred in 5% of patients, mostly low grade. ISASOCUT met its primary endpoint and supports SC isatuximab via OBI as a feasible alternative to intravenous administration.
- Open Access
- 24 October 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-7
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when possible. Lenalidomide maintenance until progression is also recommended per international guidelines. This strategy has been developed over recent decades, based on results of phase 3 trials designed and conducted by different academic groups. With these therapeutic advances, the median overall survival (OS) for patients with MM has increased from 5 years in the 1990s, to over 15 years at present. Here, we present the contribution of the French myeloma cooperative group Intergroupe Francophone du Myélome (IFM) to these advances in the newly diagnosed transplant-eligible (NDTE) setting.
- 24 October 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-7
Open Access35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when possible. Lenalidomide maintenance until progression is also recommended per international guidelines. This strategy has been developed over recent decades, based on results of phase 3 trials designed and conducted by different academic groups. With these therapeutic advances, the median overall survival (OS) for patients with MM has increased from 5 years in the 1990s, to over 15 years at present. Here, we present the contribution of the French myeloma cooperative group Intergroupe Francophone du Myélome (IFM) to these advances in the newly diagnosed transplant-eligible (NDTE) setting.
- Open Access
- 21 October 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-4
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
- 21 October 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-4
Open AccessDebulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
- Open Access
- 28 August 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (2) , 728-732
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
- 28 August 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (2) , 728-732
Open AccessAssessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
- 24 July 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (10) , 759-762
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study
- 24 July 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (10) , 759-762
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study
- Open Access
- 10 July 2025
- Published by Springer Nature in Research Square
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
T-cell redirecting immunotherapies have improved outcomes in relapsed/refractory multiple myeloma (RRMM), yet patients with extramedullary disease (EMD) and/or high tumor burden continue to fare poorly. We evaluated chemotherapy-based tumor debulking prior to anti-BCMA/CD3 bispecific antibody (BsAb) therapy in this high-risk population. In this multicenter retrospective study (15 IFM centers), RRMM patients receiving BsAb therapy after chemotherapy within the prior month were analyzed. High tumor burden included medullary/para-medullary disease or elevated monoclonal protein. High-risk cytogenetics comprised del(17p), 1q21 gain/amplification, t(4;14), or t(14;16). Forty-four patients (median age 67) were included: 93% were triple-class refractory, 50% had EMD, and 50% had high-risk cytogenetics. Chemotherapy regimens included alkylators (89%), anthracyclines (34%), and etoposide (50%). Teclistamab (70%) or elranatamab (30%) was initiated after a median of 28 days post-chemotherapy. At 12 months median follow-up, ORR post-chemotherapy was 32%. ORR with BsAb reached 64% after cycle 1, 73% after cycle 3, and 87% after cycle 6. Median progression-free survival was 10.2 months; median overall survival, 20.1 months. Chemotherapy-based debulking prior to anti-BCMA/CD3 BsAb is feasible and safe, achieving high response rates and durable outcomes in high-risk RRMM.
- 10 July 2025
- Published by Springer Nature in Research Square
Open AccessDebulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
T-cell redirecting immunotherapies have improved outcomes in relapsed/refractory multiple myeloma (RRMM), yet patients with extramedullary disease (EMD) and/or high tumor burden continue to fare poorly. We evaluated chemotherapy-based tumor debulking prior to anti-BCMA/CD3 bispecific antibody (BsAb) therapy in this high-risk population. In this multicenter retrospective study (15 IFM centers), RRMM patients receiving BsAb therapy after chemotherapy within the prior month were analyzed. High tumor burden included medullary/para-medullary disease or elevated monoclonal protein. High-risk cytogenetics comprised del(17p), 1q21 gain/amplification, t(4;14), or t(14;16). Forty-four patients (median age 67) were included: 93% were triple-class refractory, 50% had EMD, and 50% had high-risk cytogenetics. Chemotherapy regimens included alkylators (89%), anthracyclines (34%), and etoposide (50%). Teclistamab (70%) or elranatamab (30%) was initiated after a median of 28 days post-chemotherapy. At 12 months median follow-up, ORR post-chemotherapy was 32%. ORR with BsAb reached 64% after cycle 1, 73% after cycle 3, and 87% after cycle 6. Median progression-free survival was 10.2 months; median overall survival, 20.1 months. Chemotherapy-based debulking prior to anti-BCMA/CD3 BsAb is feasible and safe, achieving high response rates and durable outcomes in high-risk RRMM.
- Top Cited Papers
- 3 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (1) , 52-61
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
For patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen before autologous transplant is the standard of care. The phase 3 IFM2020-02-MRD-adapted strategy (MIDAS) study assessed a minimal residual disease (MRD)–driven consolidation and maintenance strategy after induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD). We report safety and efficacy outcomes of six 28-day cycles of IsaKRD in 791 patients. The median age was 59 years; 13% had International Staging System (ISS) stage III, 5% Revised-ISS stage III, and 8% high-risk cytogenetics (Intergroupe Francophone du Myélome linear predictor cytogenetic score of >1). Overall, 96% (N = 757) of patients completed induction. The median CD34+ cell yield was 7 × 106/kg, with 94% of patients able to proceed with a potential tandem transplant. The best overall response rate was 95%. In the intent-to-treat population, 91% achieved a very good partial response or better after induction, with MRD-negativity rates of 63% at 10−5 and 47% at 10−6. During induction, 7 patients experienced disease progression, and 5 died due to disease progression (n = 1), cardiac events (n = 2), or other causes (n = 2). The most common grade 3/4 adverse events were neutropenia (25%), thrombocytopenia (5%), and infections (7%); only 13% of patients reported any grade peripheral neuropathy. IsaKRD induction yielded deep responses and high MRD-negativity rates while ensuring successful stem cell collection, with no new safety signals. Continued follow-up of this ongoing study is required to confirm these findings. This trial was registered at www.clinicaltrials.gov as #NCT04934475.
- 3 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (1) , 52-61
Top Cited PapersIsatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
For patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen before autologous transplant is the standard of care. The phase 3 IFM2020-02-MRD-adapted strategy (MIDAS) study assessed a minimal residual disease (MRD)–driven consolidation and maintenance strategy after induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD). We report safety and efficacy outcomes of six 28-day cycles of IsaKRD in 791 patients. The median age was 59 years; 13% had International Staging System (ISS) stage III, 5% Revised-ISS stage III, and 8% high-risk cytogenetics (Intergroupe Francophone du Myélome linear predictor cytogenetic score of >1). Overall, 96% (N = 757) of patients completed induction. The median CD34+ cell yield was 7 × 106/kg, with 94% of patients able to proceed with a potential tandem transplant. The best overall response rate was 95%. In the intent-to-treat population, 91% achieved a very good partial response or better after induction, with MRD-negativity rates of 63% at 10−5 and 47% at 10−6. During induction, 7 patients experienced disease progression, and 5 died due to disease progression (n = 1), cardiac events (n = 2), or other causes (n = 2). The most common grade 3/4 adverse events were neutropenia (25%), thrombocytopenia (5%), and infections (7%); only 13% of patients reported any grade peripheral neuropathy. IsaKRD induction yielded deep responses and high MRD-negativity rates while ensuring successful stem cell collection, with no new safety signals. Continued follow-up of this ongoing study is required to confirm these findings. This trial was registered at www.clinicaltrials.gov as #NCT04934475.